Company intelligence / Profile preview

BIOCAST

Shanghai, Shanghai, Chinabiocast.com.au ↗

Ownership: Private
Development stage: Commercial

Overview

BIOCAST provides advanced humanized 3D microphysiological models ("organ on a chip") to enable more predictive preclinical studies. The company collaborates with partners to accelerate precision medicine development, notably in IBD. No direct clinical results as it does not develop therapeutics itself but supports others' pipelines.

Therapeutic areas: Gastroenterology
Modalities: Humanized 3D disease modelsOrgan-on-a-chipMicrophysiological systems
Industry: Non-Drug Biotech

Drug pipeline

1 asset

Biocast

Commercial

Indications: Plant health, Soil health

Partnerships

AlxplorerBioAliveX

Beyond the preview

Go deeper on BIOCAST.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIOCAST.

Explore the full profile